Piper Jaffray Starts Flex Pharma (FLKS) at Overweight; Sees ~70% Upside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
JMP Securities Starts Flex Pharma (FLKS) at Market Outperform
February 23, 2015 7:34 AM ESTJMP Securities initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Market Outperform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreCantor Fitzgerald Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:34 AM ESTCantor Fitzgerald initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreRoth Capital Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:33 AM ESTRoth Capital initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreJefferies Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:15 AM ESTJefferies initiates coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $25.00.
Analyst Ryan Martins comments, "FLKS' proprietary formulation of transient receptor potential (TRP) ion channel activators is well positioned to address muscle cramps and other neuromuscular... More
